The long awaited results of a seven-year research trial, known as the TACT trial, were finally released in November 2012, demonstrating a significant positive result of chelation therapy in the treatment of cardiovascular disease and prevention of negative outcomes of this disease such as stroke, heart attack, amputation and death.  TACT, which is the Trial to Assess Chelation Therapy, called on the expertise of university cardiologists and experienced chelation physicians from around the United States.  The objective of the study centered on comparisons between patients with significant cardiovascular disease, who were treated with medication and intravenous chelation therapy to those receiving medication but no chelation.

The results indicated significant improvement in patients with previous heart attacks who were already under cardiology treatment- especially patients with diabetes. The group treated with chelation had fewer subsequent surgeries than those who received a placebo.  In addition, findings show chelation reduced death from heart attacks by 18% in the group at large, and over 39% for diabetics. Although, some among conventional cardiologists have already attempted to discredit this large and well-controlled trial sponsored by the National Institutes of Health (NIH) Heart, Lung & Blood Institute as well as the National Center for Complementary & Alternative Medicine, the results speak for themselves, especially in diabetics who are at extremely high risk for vascular diseases.

I have been administering the IV treatment since 1989 in my office and have personally observed remarkable improvements in many of my patients receiving chelation therapy, both for heavy metal detoxification and for heart and vascular conditions. As a result, I have been an advocate of chelation therapy for many years. Please call or contact us for more information.

Leave a Reply